Bryan, Joshua W. and Hassoulas, Athanasios ORCID: https://orcid.org/0000-0002-1029-1847
2026.
Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis.
BMC Psychiatry
10.1186/s12888-026-07787-7
|
|
PDF
- Accepted Post-Print Version
Available under License Creative Commons Attribution. Download (1MB) |
Abstract
Objective Obsessive-compulsive disorder (OCD) is a chronic psychiatric condition for which a substantial proportion of patients do not respond adequately to first-line treatments. This review thus aimed to critically appraise the clinical literature examining memantine in obsessive-compulsive disorder, with a particular focus on individual study design, dosing strategies, tolerability, and methodological limitations. Methods A structured literature search of MEDLINE was conducted in March 2024 from database inception to March 2024. Titles, abstracts, and full texts were screened against predefined inclusion criteria, and relevant studies were synthesised narratively. A second, identical literature search was conducted in August 2025 covering March 2024 to August 2025. In total, 10 studies were included in the narrative synthesis. Results Our findings suggest that memantine may offer therapeutic benefits for OCD. Methodological issues, however, such as small sample sizes, strong geographical clustering, the exclusion of dropout data and limited use of intention-to-treat analyses, restrict the generalisability of the reported outcomes. Tolerability varied significantly by dose, with higher doses being associated with increased side effects while lower doses appeared better tolerated but elicited a poorer efficacy, although evidence was mixed. Only one study rigorously assessed treatment-refractory OCD and reported significant symptomatic improvement following longer-term memantine administration. Baseline severity, treatment expectancy, and concurrent cognitive-behavioural therapy were also identified as factors that may mediate these effects. Conclusion Overall, current evidence does not support the routine use of memantine for OCD. However, it does highlight specific methodological considerations and priorities for future rigorous investigation. Future randomised controlled trials with larger samples, longer follow-ups, and standardised dosing protocols are needed to clearly determine memantine’s role in OCD management.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | In Press |
| Schools: | Schools > Medicine |
| Publisher: | BioMed Central |
| ISSN: | 1471-244X |
| Date of First Compliant Deposit: | 19 January 2026 |
| Date of Acceptance: | 5 January 2026 |
| Last Modified: | 19 Jan 2026 13:00 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/184011 |
Actions (repository staff only)
![]() |
Edit Item |





Altmetric
Altmetric